This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bristol-Myers Squibb Fall From Favor Could Profit Patient Investors

NEW YORK (TheStreet) -- Bristol-Myers Squibb (BMY - Get Report) began 2014 with fanfare and market acclaim. After announcing the sale of its global diabetes business to AstraZeneca (AZN) for more than $4 billion, shares of BMY rocketed above $57 on March 5 shortly after the deal was completed.

Since then it's been downhill for the company's stock. By June 9 shares plunged nearly 18.5% to $46.51. Some talking heads were calling the stock "dead money" and described Bristol-Myers as a company that had sold its way into obscurity and uncertainty. Its shares closed Monday at $47.27, down nearly 12% for the year to date.

Little wonder technical chartist Helene Meisler, the editor of The Daily Swing Trade, wondered how the stock went "from so good to so bad so quickly and no one even mentions it. The fundamentalists were all over it, loving on it, and here it is down on the year."

She concluded, "In a market that doesn't get saved all the time, [its] chart measures to $40. In this market I would pay attention to the $48-$49 area. If it cannot recapture that level, then it tells us something is wrong here." So far that observation has proved accurate.

But that doesn't mean patient investors with a long time horizon can't consider BMY.

The perception that "...something is wrong here" may be based on several factors. Investors have been concerned about the company's drug pipeline and analysts have questioned its short-term ability to grow its revenue number and bottom-line earnings.

The company has been going through a purposeful transition for several years. Much of the downsizing was accomplished by selling its non-pharma assets including a wound care company, a medical imaging unit and the spinoff of what is today called Mead-Johnson Nutrition (MJN), Bristol's lucrative infant nutrition company.

The metamorphosis was so dramatic that one industry analyst described it as the most stunning witnessed in the drug sector. Jami Rubin with Goldman Sachs described Bristol's overhaul as taking the company "from a big, diversified drug company to a highly focused biopharma firm."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BMY $72.18 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs